CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...
The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research. CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results